Vnitr Lek 2025, 71(3):162-169 | DOI: 10.36290/vnl.2025.029

Triple therapy in treatment of bronchial asthma

Dana Lauková
PaF ambulancia, Interná klinika Fakultná nemocnica Nitra

The ultimate goal in the treatment of asthma is the achievement of disease control and minimization of the risk for future exacerbation. Despite using medium/high dose of inhaled corticosteroids (ICS) in fixed combination with long-acting beta-2 agonists (LABA), many patients still do not achieve an adequate level of disease control and remain at risk of exacerbations. Disease severity may be related to poor treatment adherence or improper inhaler technique. LAMA is suggested as the first add-on therapy to moderate dose ICS + LABA (GINA 2024), called as triple therapy. GINA recommends triple therapy (LAMA to ICS/LABA) as a further option at step 4 and as first choice at step 5. Therefore, it is useful to know strategy this treatment and adequate indicate free and fixed triple therapy in patients with bronchial asthma. It offers to achieve therapeutic control of asthma. Despite evidence of its efficacy and safety, inhaled triple therapy (ITT) is still not mostly used in patients with asthma.

Keywords: asthma control, inhaled triple therapy, therapeutic control of asthma.

Accepted: April 28, 2025; Published: May 16, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lauková D. Triple therapy in treatment of bronchial asthma. Vnitr Lek. 2025;71(3):162-169. doi: 10.36290/vnl.2025.029.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2017. Available from: https://ginasthma.org/wp-content/uploads/2019/01/2017-GINA.pdf.
    2. Bagnasco D, Ansotegui I, Baiardinia I, et al. Triple inhaled therapy in asthma: Beliefs, behaviours and doubts. Pulm Pharmacol Therap. 2024;87:102333. doi: 10.1016/j.pupt.2024.102333. Epub 2024 Nov 19. Go to original source... Go to PubMed...
    3. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2024. Available from: https://ginasthma.org/wp-content/uploads/2024/05/GINA-2024-Strategy-Report-24_05_22_WMS.pdf.
    4. Rodrigo GJ, Rodrigo C. Triple Inhaled Drug Protocol for the Treatment of Acute Severe Asthma*. CHEST. 2003;123(6):1908-15. Go to original source... Go to PubMed...
    5. Aalbers R, Park HS. Positioning of long-acting musca rinic antagonists in the management of asthma. Allergy Asthma Immunol Res. 2017;9(5):386-393 Go to original source... Go to PubMed...
    6. Gosens R, Gross N. Gosens R, Gross N. The mode of action of anticholinergics in asthma. Eur Respir J. 2018;52:1701247. Go to original source... Go to PubMed...
    7. Quirce S, Dominguez-Ortega J, Barranco P. Anticholinergics for treatment of asthma. J Investig Allergol Clin Immunol. 2015;25:84-93.
    8. Haney S, Hancox RJ. Recovery from bronchoconstriction and bronchodilator tolerance. Clin Rev Allergy Immunol. 2006;31:181-196. Go to original source... Go to PubMed...
    9. Kerstjens HA, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012;367:1198-1207. Go to original source... Go to PubMed...
    10. Luz MI, Aguiar R, Morais-Almeida M. The reality of LAMAs for adult asthmatic patients. Expert Rev Resp Med, Expert Rev Respir Med. 2020 Nov;14(11):1087-1094. doi: 10.1080/17476348.2020.1794828. Epub 2020 Jul. Go to original source... Go to PubMed...
    11. Calzetta A, Coppola B, et al. The Impact of Muscarinic Receptor Antagonists on Airway Inflammation: A Systematic Review. International Journal of Chronic Obstructive Pulmonary Disease. 2021;16:257-279. Go to original source... Go to PubMed...
    12. Wechsler ME, Oppenheimer JJ. Open-inhaler versus single-inhaler triple therapy (long-acting muscarinic antagonist, inhaled corticosteroid, and long-acting β2-agonist) in asthma patients: a narrative review. Journal of asthma. 2023;60(9):1633-1645. Go to original source... Go to PubMed...
    13. Gessner C, Kornmann O, Maspero J, et al. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate oncedaily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: a randomised, phase IIIb, non-inferiority study (ARGON) [published correction appears in Respir Med. 2020 Dec;175:106186]. Respir Med. 2020;170:106021. Go to original source... Go to PubMed...
    14. Lazarus SC, Krishnan JA, King TS, et al. Mometasone or tiotropium in mild asthma with a low sputum eosinophil level. N Engl J Med. 2019;380(21):2009-2019. Go to original source... Go to PubMed...
    15. Bos IS, Gosens R, Zuidhof AB, Schaafsma D, Halayko AJ, Meurs H, Zaagsma J. Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison. Eur Respir J. 2007;30(4):653-661. Go to original source... Go to PubMed...
    16. Cazzola M, Puxeddu E, Matera MG, Rogliani P. A potential role of triple therapy for asthma patients. Expert Rev Respir Med. 2019;13(11):1079-1085. Go to original source... Go to PubMed...
    17. Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI) administered and coordinated National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC), M.M. Cloutier, A.P. Baptist, K. V. Blake, E.G. Brooks, T. Bryant-Stephens, E. DiMango, A.E. Dixon, K.S. Elward, T. Hartert, J.A. Krishnan, R.F. Lemanske Jr., D.R. Ouellette, W.D. Pace, M. Schatz, N.S. Skolnik, J.W. Stout, S.J. Teach, C.A. Umscheid, C.G. Walsh, 2020 focused updates to the asthma management guidelines: a report from the national asthma education and prevention Program coordinating committee expert panel working group, J. Allergy Clin. Immunol. 2020;146(6):1217-1270. Go to original source... Go to PubMed...
    18. Lee LA, Bailes Z, Barnes N, et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med. 2021;9(1):69-84. -1.Epub 2020 Sep 9. Erratum in: Lancet Respir Med. 2021 Jan 4: PMID: 32918892 Go to original source... Go to PubMed...
    19. Kerstjens HAM, Moroni-Zentgraf P, Tashkin DP, et al. Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status. Respir Med.2016;117:198-206. Go to original source... Go to PubMed...
    20. Paggiaro P, Halpin DM, Buhl R, et al. The effect of tiotropium in symptomatic asthma despite low- to medium-dose inhaled corticosteroids: a randomized controlled trial. J Allergy Clin Immunol Pract. 2016;4:104-113.e2.Další literatura u autorky a na www.casopisvnitrnilekarstvi.cz Go to original source... Go to PubMed...
    21. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2018. Dostupné na: https://ginasthma.org/wp-content/uploads/2018/04/wms-GINA-2018-report-V1.3-002.pdf.
    22. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2019. Dostupné na: https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf.
    23. Abadoglu O, Berk S. Tiotropium may improve asthma symptoms and lung function in asthmatic patients with irreversible airway obstruction: the reallife data. Clin Respir J. 2016;10(4):421-427. Go to original source... Go to PubMed...
    24. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2021. Dostupné na: https://ginasthma.org/wp-content/uploads/ 2021/05/GINA-Main-Report-2021-V2-WMS.pdf.
    25. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention.; 2020. Dostupné na: https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf.
    26. Virchow JC, Kuna P, Paggiaro P, et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel group, randomized, controlled phase 3 trials. Lancet. 2019;394(10210):1737-1749. Go to original source... Go to PubMed...
    27. Mangia PP, Gallo O, Ritrovato D, Pradelli L. CostUtility Analysis of FixedDose Combination of Indacaterol Acetate Glycopyrronium Bromide and Mometasone Furoate as a Maintenance Treatment in Adult Patients with Asthma Not Adequately Controlled with a Maintenance Combination of a LongActing BetaAgonist and a High Dose of an Inhaled Corticosteroid Who Experienced One or More Asthma Exacerbations in the Previous Year. Clinical Drug Investigation. 2021;41:785-794. Go to original source... Go to PubMed...
    28. Kerstjens HAM, Maspero J, Chapman KR, et al. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respir Med. 2020;8(10):1000-12. Go to original source... Go to PubMed...
    29. Paggiaro P, Kuna P, Kots M, et al. Efficacy and safety of a fixed combination extrafine beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide (BDP/FF/GB) pMDI treatment compared to fixed combination BDP/FF in patients with uncontrolled asthma on medium dose ICS/LABA: the TRIMARAN study. Am J Respir Crit Care Med. 2019;199:A7080. Go to original source...
    30. Virchow JC, Canonica WG, Paggiaro P, et al. Reducing the rate of severe asthma exacerbations using single-inhaler extrafine BDP/FF/GB combination compared to BDP/FF in patients with uncontrolled asthma: pooled results from the TRIMARAN and TRIGGER studies.Am J Respir Crit Care Med. 2019;394(10210):1737-1749. Go to original source...
    31. Daley-Yates PT. Inhaled corticosteroids: potency, dose equivalence and therapeutic index. Br. J Clin Pharmacol 2015;80(3):372-380. Go to original source... Go to PubMed...
    32. Averell CM, Stanford R, Laliberte F, Wu JW, Germain G, Duh MS. Medication adherence in patients with asthma using once daily versus twice daily ICS/LABAs. J Asthma. 2021;58(1):102-111. Go to original source... Go to PubMed...
    33. Price DB, Colice G, Israel E, Roche N, Postma DS, Guilbert TW, van Aalderen WMC, Grigg J, Hillyer EV, Thomas V, et al. Add-on LABA in separate inhaler as asthma step-up therapy versus increased dose of ICS or ICS/LABA combination inhaler. ERJ Open Res. 2016;2:00106-2015. Go to original source... Go to PubMed...
    34. Chapman KR, Balter M, Bhinder S, Kaplan A, et al. Triple inhaled therapy for asthma in Canada, Can J Respir, Crit Care Sleep Med, 2023;7:5, 250-257. Go to original source...
    35. Yang CL, Hicks EA, Mitchell P, et al. Canadian Thoracic Society 2021 Guideline update: Diagnosis and management of asthma in preschoolers, children and adults. Can J Respir Crit Care Sleep Med. 2021;5(6):348-361. Go to original source...
    36. Busse WW, Kraft M. Current unmet needs and potential solu tions to uncontrolled asthma. Eur Respir Rev. 2022;31:210176. Go to original source... Go to PubMed...
    37. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2022. https://ginasthma.org/wp-content/uploads/2023/05/GINA-Main-Report-2022-WMSA.pdf.
    38. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2023. https://ginasthma.org/wp-content/uploads/2023/07/GINA-2023-Pocket-Guide-WMS.pdf.
    39. Mortimer K, Masekela R, Ozoh O, et al. The reality of managing asthma in sub-Saharan Africa - priorities and strategies for improving care. J Pan Afr Thorac Soc. 2022;3:105-120, Go to original source...
    40. Rogliani P, Cavalli F, Chetta A, Cazzola M, Calzetta L. Potential drawbacks of ICS/LABA/LAMA triple fixed-dose combination thera py in the treatment of asthma: a quantitative synthesis of safety pro f ile. J Asthma Allergy. 2022;15:565-577 Go to original source... Go to PubMed...
    41. Kim LHY, Saleh C, Whalen-Browne A, O'Byrne PM, Chu DK. Triple vs dual inhaler therapy and asthma outcomes in moderate to severe asthma: a systematic review and meta-analysis. JAMA. 2021;325(24):2466-2479. Go to original source... Go to PubMed...
    42. SPIRIVA Product Monograph. 2022. https://pdf.hres.ca/dpd_ pm/00065560.PDF.
    43. Enerzair Product Monograph. 2021. https://pdf.hres.ca/dpd_ pm/00063748.PDF
    44. Trelegy Product Monograph. 2022. https://pdf.hres.ca/dpd_ pm/00068965.PDF
    45. BREZTRI™ AEROSPHERE® Product Monograph. 2021. https:// pdf.hres.ca/dpd_pm/00062143.PDF.
    46. Fulford B, Mezzi K, Whiting A, Aumônier S. Life-cycle assess ment of the breezhaler® breath-actuated dry powder inhaler. Sustainability. 2021;13(12):6657. Go to original source...
    47. Singh D, Virchow JC, Canonica GV, et al. Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER, Respir. Res. 2020;21(1):285. Go to original source... Go to PubMed...
    48. Lommatzsch M, Buhl R, Canonica GW, et al. Pioneering a paradigm shift in asthma management: remission as a treatment goal, Lancet, Respir. Med. 2024;12(2):96-99. Go to original source... Go to PubMed...
    49. Puggioni F, Brussino L, Canonica GW, et al. Severe Asthma Network in Italy (SANI) group, Frequency of tiotropium bromide use and clinical features of patients with severe asthma in a real-life setting: data from the severe asthma network in Italy (SANI) Registry, J. Asthma Allergy. 2020;13:599-604. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.